These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 6109045)

  • 1. [Psychological aspects of depot treatment of schizophrenic syndromes].
    Jacobsson L; Odling H
    Lakartidningen; 1980 Oct; 77(40):3522-6. PubMed ID: 6109045
    [No Abstract]   [Full Text] [Related]  

  • 2. [Is depot formulation a long-term optimal treatment option?].
    Musch A
    Med Monatsschr Pharm; 2005 Nov; 28(11):414-6. PubMed ID: 16309031
    [No Abstract]   [Full Text] [Related]  

  • 3. Depot neuroleptic therapy: clinical considerations.
    Remington GJ; Adams ME
    Can J Psychiatry; 1995 Apr; 40(3 Suppl 1):S5-11. PubMed ID: 7627927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Long-term therapy with depot neuroleptics. Prevention of recurrence in chronic schizophrenic patients].
    Bergener M; Husser J; Kranzhoff EU; Charap A
    Fortschr Med; 1986 Oct; 104(40):756-60. PubMed ID: 2877927
    [No Abstract]   [Full Text] [Related]  

  • 5. The case for long-acting antipsychotic agents in the post-CATIE era.
    Nasrallah HA
    Acta Psychiatr Scand; 2007 Apr; 115(4):260-7. PubMed ID: 17355516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The attitude of patients towards antipsychotic depot treatment.
    Heres S; Schmitz FS; Leucht S; Pajonk FG
    Int Clin Psychopharmacol; 2007 Sep; 22(5):275-82. PubMed ID: 17690596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Substance abuse and the management of medication nonadherence in schizophrenia.
    Wilk J; Marcus SC; West J; Countis L; Hall R; Regier DA; Olfson M
    J Nerv Ment Dis; 2006 Jun; 194(6):454-7. PubMed ID: 16772865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pharmacological standards in schizophrenia treatment].
    Jarema M; Kiejna A; Landowski J; Meder J; Jolanta RJ; Rybakowski J
    Psychiatr Pol; 2006; 40(6):1171-205. PubMed ID: 17444297
    [No Abstract]   [Full Text] [Related]  

  • 9. [Long-term treatment of outpatients with depot neuroleptics (author's transl)].
    Saameli W
    Schweiz Rundsch Med Prax; 1981 Feb; 70(6):206-10. PubMed ID: 6113584
    [No Abstract]   [Full Text] [Related]  

  • 10. Longterm maintenance therapy with depot haloperidol in schizophrenia.
    Zbytovský J
    Homeost Health Dis; 1991; 33(5-6):287. PubMed ID: 18265499
    [No Abstract]   [Full Text] [Related]  

  • 11. [Schizophrenia: prophylaxis prevents recurrence. Low dose depot neuroleptics--an exit from the "revolving door" psychiatry].
    Fortschr Med Suppl; 1993; 147():1-15. PubMed ID: 9260317
    [No Abstract]   [Full Text] [Related]  

  • 12. [Importance of pharmacotherapy in the rehabilitation of schizophrenic patients].
    Wojdysławska I
    Psychiatr Pol; 1977; 11(6):683-8. PubMed ID: 25450
    [No Abstract]   [Full Text] [Related]  

  • 13. A pharmacoeconomic model of outpatient antipsychotic therapy in "revolving door" schizophrenic patients.
    Glazer WM; Ereshefsky L
    J Clin Psychiatry; 1996 Aug; 57(8):337-45. PubMed ID: 8752015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eleven years of experience with depot neuroleptics.
    Gross H; Kaltenbäck E; Pfolz H
    Acta Psychiatr Belg; 1981; 81(2):128-32. PubMed ID: 6117183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Depot neuroleptics in social psychiatric practice].
    Pruss U; Rose HK; Zechner A
    Psychiatr Prax; 1984 Jul; 11(4):101-8. PubMed ID: 6148764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prolonged action neuroleptics and the relationship between physician, patient and family].
    Boudef M
    Sante Ment Que; 1995; 20(1):233-47. PubMed ID: 7578708
    [No Abstract]   [Full Text] [Related]  

  • 17. Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia.
    Marinis TD; Saleem PT; Glue P; Arnoldussen WJ; Teijeiro R; Lex A; Latif MA; Medori R
    Pharmacopsychiatry; 2007 Nov; 40(6):257-63. PubMed ID: 18030649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Depot neuroleptics: the relevance of psychosocial factors--a United States perspective.
    Hogarty GE
    J Clin Psychiatry; 1984 May; 45(5 Pt 2):36-42. PubMed ID: 6143746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Raising the bar for treatment expectations in schizophrenia: achieving remission as a routine goal of antipsychotic pharmacotherapy.
    Nasrallah HA; Dursun SM
    J Psychopharmacol; 2006 Nov; 20(6 Suppl):3-5. PubMed ID: 17046983
    [No Abstract]   [Full Text] [Related]  

  • 20. [Modification of long-term schizophrenia by somato-therapeutic measures].
    Gross G; Huber G; Schüttler R
    Psychiatr Clin (Basel); 1980; 13(3-4):179-92. PubMed ID: 6113621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.